

104TH CONGRESS
2D SESSION

S. 1656

To permit individuals to continue health plan coverage of services while participating in approved clinical studies.

IN THE SENATE OF THE UNITED STATES

MARCH 29, 1996

Ms. SNOWE introduced the following bill; which was read twice and referred to the Committee on Labor and Human Resources

A BILL

To permit individuals to continue health plan coverage of services while participating in approved clinical studies.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Improved Patient Ac-
5 cess to Clinical Studies Act of 1996”.

6 **SEC. 2. COVERAGE FOR INDIVIDUALS PARTICIPATING IN**
7 **APPROVED CLINICAL STUDIES.**

8 (a) PERMITTING PARTICIPATION IN APPROVED CLIN-
9 ICAL STUDIES.—A health plan may not deny (or limit or

1 impose additional conditions on) coverage of items and
 2 services furnished to an enrollee if—

3 (1) the enrollee is participating in an approved
 4 clinical study,

5 (2) the items and services are furnished accord-
 6 ing to the design of the study or to treat conditions
 7 resulting from participation in the study, and

8 (3) the items and services would otherwise be
 9 covered under the plan except for the fact that they
 10 are provided in connection with participation in such
 11 a study.

12 A health plan may not discriminate against an enrollee
 13 on the basis of the enrollee’s participation in such a study.

14 (b) CONSTRUCTION.—Nothing in subsection (a) shall
 15 be construed as requiring a health plan to provide for pay-
 16 ment for items and services normally paid for as part of
 17 an approved clinical study.

18 (c) APPROVED CLINICAL STUDY DEFINED.—In this
 19 section, the term “approved clinical study” means—

20 (1) a research study approved by the Secretary
 21 of Health and Human Services, the Director of the
 22 National Institutes of Health, the Commissioner of
 23 the Food and Drug Administration, the Secretary of
 24 Veterans Affairs, the Secretary of Defense, or a
 25 qualified nongovernmental research entity (as de-

1 fined in guidelines of the National Institutes of
2 Health), or

3 (2) a peer-reviewed and approved research pro-
4 gram, as defined by the Secretary of Health and
5 Human Services, conducted for the primary purpose
6 of determining whether or not a treatment is safe,
7 efficacious, or having any other characteristic of a
8 treatment which must be demonstrated in order for
9 the treatment to be medically necessary or appro-
10 priate.

○